Research Analysts Set Expectations for UBX FY2026 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Unity Biotechnology in a research report issued on Monday, March 24th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.65) per share for the year, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital reduced their target price on Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday.

Unity Biotechnology Trading Down 1.7 %

Shares of NASDAQ:UBX opened at $1.18 on Thursday. The company has a 50 day moving average of $1.88 and a 200 day moving average of $1.51. The stock has a market cap of $19.90 million, a P/E ratio of -0.90 and a beta of 1.02. Unity Biotechnology has a 12 month low of $0.94 and a 12 month high of $3.10.

Hedge Funds Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC raised its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 at the end of the most recent reporting period. 29.49% of the stock is currently owned by institutional investors and hedge funds.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.